|
1
|
Hjertner O, Qvigstad G, HjorthHansen H,
Seidel C, Woodliff J, Epstein J, Waage A, Sundan A and Börset M:
Expression of urokinase plasminogen activator and the urokinase
plasminogen activator receptor in myeloma cells. Br J Haematol.
109:815–822. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tarui T, Mazar AP, Cines DB and Takada Y:
Urokinase-type plasminogen activator receptor (CD87) is a ligand
for integrins and mediates cell-cell interaction. J Biol Chem.
276:3983–3990. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mekkawy AH, Pourgholami MH and Morris DL:
Involvement of urokinase-type plasminogen activator system in
cancer: An overview. Med Res Rev. 34:918–956. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DeClerck YA and Jones PA: Effect of
ascorbic acid on the resistance of the extracellular matrix to
hydrolysis by tumor cells. Cancer Res. 40:3228–3231.
1980.PubMed/NCBI
|
|
5
|
Reuning U, Sperl S, Kopitz C, et al:
Urokinase-type plasminogen activator (uPA) and its receptor (uPAR):
Development of antagonists of uPA/uPAR interaction and their
effects in vitro and in vivo. Curr Pharm Des.
9:1529–1543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lanza F, Castoldi GL, Castagnari B, et al:
Expression and functional role of urokinase-type plasminogen
activator receptor in normal and acute leukemic cells. Br J
Haematol. 103:110–123. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei Y, Yang X, Liu Q, et al: A role for
caveolin and the urokinase receptor in integrinmediated adhesion
and signaling. J Cell Biol. 144:1285–1294. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kindzelskii AL, Amhad I, Keller D, et al:
Pericellular proteolysis by leukocytes and tumor cells on
substrates: Focal activation and the role of urokinase-type
plasminogen activator. Histochem Cell Biol. 121:299–310. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fazioli F, Resnati M, Sidenius N, et al: A
urokinase-sensitive region of the human urokinase receptor is
responsible for its chemotactic activity. EMBO J. 16:7279–7286.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gyetko MR, Todd RF III, Wilkinson CC and
Sitrin RG: The urokinase receptor is required for monocyte
chemotaxis in vitro. J Clin Invest. 93:1380–1387. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Béné MC, Castoldi G, Knapp W, et al: CD87
(urokinase-type plasminogen activator receptor), function and
pathology in hematological disorders: A review. Leukemia.
18:394–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei Y, Eble JA, Wang Z, Kreidberg JA and
Chapman HA: Urokinase receptors promote beta1 integrin function
through interactions with integrin alpha3beta1. Mol Biol Cell.
12:2975–2986. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gyetko MR, Sitrin RG, Fuller JA, Todd RF
III, Petty H and Standiford TJ: Function of the urokinase receptor
(CD87) in neutrophil chemotaxis. J Leukoc Biol. 58:533–538.
1995.PubMed/NCBI
|
|
14
|
Gyetko MR, Chen GH, McDonald RA, Goodman
R, Huffnagle GB, Wilkinson CC, Fuller JA and Toews GB: Urokinase is
required for the pulmonary inflammatory responseto Cryptococcus
neoformans: A murine transgenic model. J Clin Invest. 97:1818–1826.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei Y, Lukashev M, Simon DI, Bodary SC,
Rosenberg S, Doyle MV and Chapman HA: Regulation of integrin
function by the urokinase receptor. Science. 273:1551–1555. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Daci E, Udagawa N, Martin TJ, Bouillon R
and Carmeliet G: The role of the plasminogen system in bone
resorption in vitro. J Bone Miner Res. 14:946–952. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hjertner O, Qvigstad G, HjorthHansen H,
Seidel C, Woodliff J, Epstein J, Waage A, Sundan A and Börset M:
Expression of urokinase plasminogen activator and the urokinase
plasminogen activator receptor in myeloma cells. Br J Haematol.
109:815–822. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kara IO, Sahin B, Paydas S and Cetiner S:
Flow cytometric evaluation of bone marrow plasma cells using CD19,
CD45, CD56, CD38, and CD138 and correlation with bone marrow
infiltration ratio in multiple myeloma patients. Saudi Med J.
25:1587–1592. 2004.PubMed/NCBI
|
|
19
|
Rawstron A, Barrans S, Blythe D, Davies F,
English A, Pratt G, Child A, Morgan G and Jack A: Distribution of
myeloma plasma cells in peripheral blood and bone marrow correlates
with CD56 expression. Br J Haematol. 104:138–143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rigolin GM, Tieghi A, Ciccone M, Bragotti
LZ, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra
G, Cuneo A, et al: Soluble urokinase-type plasminogen activator
receptor (suPAR) as an independent factor predicting worse
prognosis and extra-bone marrow involvement in multiple myeloma
patients. Br J Haematol. 120:953–959. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hjertner O, Qvigstad G, HjorthHansen H, et
al: Expression of urokinase plasminogen activator and the urokinase
plasminogen activator receptor in myeloma cells. Br J Haematol.
109:815–822. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo LH, Xu GB and Lu XG: Detection and
clinical significance of plasma urokinase-type plasminogen
activator and its soluble receptor in patients with multiple
myeloma. Zhejiang Da Xue Xue Bao Yi Xue Ban. 32:529–532. 2003.(In
Chinese). PubMed/NCBI
|
|
23
|
Plesner T, Behrendt N and Ploug M:
Structure, function and expression on blood and bone marrow cells
of the urokinase-type plasminogen activator receptor, uPAR. Stem
Cells. 15:398–408. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wohn KD, Kanse SM, Deutsch V, Schmidt T,
Eldor A and Preissner KT: The urokinase-receptor (CD87) is
expressed in cells of the megakaryoblastic lineage. Thromb Haemost.
77:540–547. 1997.PubMed/NCBI
|
|
25
|
Stephens RW, Nielsen HJ, Christensen IJ,
ThorlaciusUssing O, Sørensen S, Danø K and Brünner N: Plasma
urokinase receptor levels in patients with colorectal cancer:
Relationship to prognosis. J Natl Cancer Inst. 91:869–874. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krüger A, Soeltl R, Lutz V, Wilhelm OG,
Magdolen V, Rojo EE, Hantzopoulos PA, Graeff H, Gänsbacher B and
Schmitt M: Reduction of breast carcinoma tumor growth and lung
colonization by overexpression of the soluble urokinase-type
plasminogen activator receptor (CD87). Cancer Gene Ther. 7:292–299.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mustjoki S, Sidenius N, Sier CF, Blasi F,
Elonen E, Alitalo R and Vaheri A: Soluble urokinase receptor levels
correlate with number of circulating tumor cells in acute myeloid
leukemia and decrease rapidly during chemotherapy. Cancer Res.
60:7126–7132. 2000.PubMed/NCBI
|
|
28
|
Miyake H, Hara I, Yamanaka K, Arakawa S
and Kamidono S: Elevation of urokinase-type plasminogen activator
and its receptor densities as new predictors of disease progression
and prognosis in men with prostate cancer. Int J Oncol. 14:535–541.
1999.PubMed/NCBI
|
|
29
|
Riisbro R, Stephens RW, Brünner N,
Christensen IJ, Nielsen HJ, Heilmann L and von Tempelhoff GF:
Soluble urokinase plasminogen activator receptor in preoperatively
obtained plasma from patients with gynecological cancer or benign
gynecological diseases. Gynecol Oncol. 82:523–531. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fernebro E, Madsen RR, Fernö M, Brünner N,
Bendahl P, Christensen IJ, Johnson A and Nilbert M: Prognostic
importance of the soluble plasminogen activator receptor, suPAR, in
plasma from rectal cancer patients. Eur J Cancer. 37:486–491. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koolwijk P, Sidenius N, Peters E, Sier CF,
Hanemaaijer R, Blasi F and van Hinsbergh VW: Proteolysis of the
urokinase-type plasminogen activator receptor by
metallopoteinase-12: Implication for angiogenesis in fibrin
matrices. Blood. 97:3123–3131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greipp PR, Lust JA, O'Fallon WM, Katzmann
JA, Witzig TE and Kyle RA: Plasmal cell labeling index and beta
2-microglobulin predict survival independent of thymidime kinase
C-reactive protein in multiple myeloma. Blood. 81:3382–3387.
1993.PubMed/NCBI
|
